Black Diamond Therapeutics, Inc. (BDTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$30.9M
Cash & Equivalents
$10.2M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$109M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutati... | PHASE2 | Active Not Recruiting | 200 |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | PHASE2 | Recruiting | 162 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.